H.C. Wainwright analyst Robert Burns double downgraded Replimune (REPL) to Sell from Buy without a price target after the FDA issued another complete response letter for RP1 plus Opdivo in anti-PD1 failed melanoma patients. The firm awaits clarity on the regulatory path forward and the revised timeline to potential submission of the RP1 dossier.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune downgraded to Underweight from Neutral at JPMorgan
- Replimune downgraded to Hold from Buy at Jefferies
- Replimune downgraded to Underperform from Market Perform at BMO Capital
- Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald
- Replimune says FDA’s CRL for RP1 ‘disappointing’